Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.
about
Resveratrol for treatment of type 2 diabetes mellitusEffects of beta-cell rest on beta-cell function: a review of clinical and preclinical dataCongenital hyperinsulinism and glucose hypersensitivity in homozygous and heterozygous carriers of Kir6.2 (KCNJ11) mutation V290M mutation: K(ATP) channel inactivation mechanism and clinical management.Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels.Compensatory Islet Response to Insulin Resistance Revealed by Quantitative Proteomics.Dopamine-mediated autocrine inhibitory circuit regulating human insulin secretion in vitroFuture detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.Use of somatostatin analogues in obesity.Genetic and biochemical pathways of beta-cell failure in type 2 diabetes.Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model.Hydrogen sulphide: novel opportunity for drug discovery.Role of SST, CORT and ghrelin and its receptors at the endocrine pancreas.TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway.Determination of heavy metal content and lipid profiles in mussel extracts from two sites on the moroccan atlantic coast and evaluation of their biological activities on MIN6 pancreatic cells.Role of resveratrol in the management of insulin resistance and related conditions: Mechanism of action.A new benzoxazine compound blocks KATP channels in pancreatic beta cells: molecular basis for tissue selectivity in vitro and hypoglycaemic action in vivo.A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice with a dominant-negative mutant hepatocyte nuclear factor-1alpha.
P2860
Q24188321-48F4B0B0-73D0-4235-B9CC-486DADDD01A9Q31144148-56813EC3-35F5-492F-B128-E6582C76D975Q34448663-9492240F-070A-435D-999C-F344263485C0Q35655010-B570E0B9-2B55-48BF-B604-91C7B094794CQ35849373-2D709E20-899A-4541-B13B-69EF7BDD19C5Q36191447-0B3940BC-4B14-44F0-AD44-38345A2D60C9Q36279518-BAE2AEA2-50E9-474B-9448-24875FAF89BFQ36402230-84DFFC4D-81EC-4D8D-B912-8B81E00D393DQ37263193-D66C1DE6-2EBE-4287-9E8B-46B58D248D32Q37611925-69B8334F-224D-434C-8BA1-62745A2243A9Q38012434-7DFC9A70-BB53-4CB8-8F8C-6B2469594F12Q38051531-5EF4DEA4-FDF5-4654-B79D-E08AAACF3E9EQ38060718-9FFD6E1A-2A40-4D15-9D04-9174AB046184Q38435784-893E99DE-12DA-4B98-BAF4-1A55C53E0A5AQ38917474-ADB988F1-C1BF-4AFF-843D-333E57E69EA0Q39432694-D006ABB5-F21E-41E5-8842-6AEEF6AFDE7BQ40216800-4BFB35B5-5E72-4CF9-B619-4DF65054DDF4Q46937429-EB8399D6-7BA9-4DD2-B835-EC53D5F38F4E
P2860
Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Inhibition of insulin secretio ...... atment of metabolic disorders.
@ast
Inhibition of insulin secretio ...... atment of metabolic disorders.
@en
type
label
Inhibition of insulin secretio ...... atment of metabolic disorders.
@ast
Inhibition of insulin secretio ...... atment of metabolic disorders.
@en
prefLabel
Inhibition of insulin secretio ...... atment of metabolic disorders.
@ast
Inhibition of insulin secretio ...... atment of metabolic disorders.
@en
P2093
P356
P1476
Inhibition of insulin secretio ...... atment of metabolic disorders.
@en
P2093
J Bondo Hansen
Per O G Arkhammar
Philip Wahl
Thora B Bodvarsdottir
P304
P356
10.2174/0929867043365026
P577
2004-06-01T00:00:00Z